Advertisement Pharmaceutical Business review - Page 5 of 5268 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 10, 2026

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea.

Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise bofanglutide in South Korea. Credit: Gan & Lee Pharmaceuticals / PR Newswire.